{"schema_version":"secwatch.filing_event.v1","accession":"0001520138-22-000548","form_type":"8-K","ticker":"BIVI","cik":"0001580149","company_name":"BIOVIE INC.","filed_at":"2022-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.263233+00:00","generated_at":"2026-06-21T08:53:01.043567+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioVie announces positive Phase 2 results for NE3107 in Parkinson's and Alzheimer's; epigenetic age reduced 3.3 years","bullets":["PD trial: NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone; under-70 patients saw 6-point superiority.","AD trial: 2.1-point improvement on ADAS-Cog12 (p=0.0173) in MCI/mild AD patients; CSF p-tau reduced by 1.66 pg/mL.","18 of 22 AD patients showed improvement on functional MRI; no drug-related adverse events reported.","DNA methylation analysis: Horvath SkinBlood clock reduced by 3.3 years (p=0.0021) after 3 months; 19 of 22 patients showed reduction.","Full Parkinson's data to be presented at AD/PD 2023 conference in March-April 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001520138-22-000548","json":"https://secwatch.observer/filing/0001520138-22-000548.json","markdown":"https://secwatch.observer/filing/0001520138-22-000548.md","text":"https://secwatch.observer/filing/0001520138-22-000548.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580149/000152013822000548/0001520138-22-000548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580149/000152013822000548/bivi-20221205_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:53:01.043567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}